Financial Performance - In the first half of 2025, the company achieved operating revenue of ¥484,236,510.36, representing a year-on-year growth of 12.81% [2] - The net profit attributable to shareholders was ¥177,008,721.63, an increase of 18.61% compared to the same period last year [2] - Sales revenue from dust mite drops was ¥454,655,215.07, up 10.51% year-on-year [2] - Sales revenue from Artemisia pollen sublingual drops reached ¥21,020,536.26, marking a significant growth of 71.37% [2] - Sales revenue from skin prick solution was ¥6,327,765.88, showing a remarkable increase of 104.38% [3] R&D Pipeline - The "Dust Mite Membrane Agent" entered Phase I clinical trials in March 2025, aimed at enhancing the existing dust mite drop product [3] - The "Dermatitis Diagnostic Patch 02" received approval for clinical trials in May 2025 and entered Phase I trials in August 2025 [3] - The company is expanding its product pipeline in the field of allergic disease diagnostics, addressing various types of allergens [3][4] Sales and Marketing Strategy - The company has promoted a group of young sales managers since the second half of last year, aiming to enhance regional responsibilities and management efficiency [4] - The positioning of skin prick solutions is evolving from auxiliary desensitization products to primary allergen screening tools [4] Future Outlook - The sales outlook for the second half of 2025 for Artemisia pollen sublingual drops is anticipated to be positive, with further details to be disclosed in upcoming reports [5] - The company aims to enrich its pipeline of allergen products and enhance market competitiveness [6][10] - Ongoing research includes mesenchymal stem cell therapies and new antibiotics for drug-resistant tuberculosis, currently in preclinical stages [7][10]

| 代码 | 简称 | 连续持有期数 | 社保基金家数 | 持股量（万股） | 环比（%） | 占流通股比例（%） | | --- | --- | --- | --- | --- | --- | --- | | 600486 | 扬农化工 | 43 | 1 | 1630.80 | -4.30 | 4.05 | | 300357 | 我武生物 | 43 | 1 | 2608.11 | 不变 | 5.39 | | 600031 | 三一重工 | 33 | 2 | 17139.44 | -2.50 | 2.02 | | 601128 | 常熟银行 | 30 | 4 | 27779.13 | -0.57 | 8.38 | | 300487 | 蓝晓科技 | 29 | 1 | 494.99 | 不变 | 1.61 | | 300196 | 长海股份 | 28 | 1 | 412.29 | 不变 | 1.68 | | 300685 | 艾德生物 | 26 | 1 | 512.15 | -52.54 | 1.31 | | 002847 | 盐津铺子 | 23 | 1 | 171.28 | -53.00 | 0.70 | | ...

2025年8月22日，我武生物(300357.SZ)发布2025年中报。 公司营业总收入为4.84亿元，较去年同报告期营业总收入增加5497.95万元，实现2年连续上涨，同比较 去年同期上涨12.81%。归母净利润为1.77亿元，较去年同报告期归母净利润增加2777.77万元，实现2年 连续上涨，同比较去年同期上涨18.61%。经营活动现金净流入为2.01亿元，较去年同报告期经营活动现 金净流入增加9825.40万元，同比较去年同期上涨96.08%。 公司最新总资产周转率为0.18次，较去年同期总资产周转率增加0.01次，同比较去年同期上涨7.57%。 最新存货周转率为0.42次，较去年同期存货周转率增加0.06次，同比较去年同期上涨15.82%。 公司股东户数为3.46万户，前十大股东持股数量为3.06亿股，占总股本比例为58.41%，前十大股东持股 情况如下： | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 浙江我武管理咨询有限公司 | 38.86% | | 2 胡康熙 | | 8.35% | | య | 全国社保基金 -- 二组合 | 4.98% | | 4 ...

Core Viewpoint - Iwubio announced the convening of its 13th meeting of the 5th Board of Directors on August 21, 2025, to review various proposals, including amendments to existing documents [2] Financial Performance - For the first half of 2025, Iwubio reported that its revenue composition was 99.59% from pharmaceutical manufacturing and 0.41% from other businesses [2]

（文章来源：证券日报） 证券日报网讯 8月21日晚间，我武生物发布公告称，公司第五届监事会第十次会议审议通过了《公司 2025年半年度报告及其摘要》等多项议案。 ...

证券日报网讯 8月21日晚间，我武生物发布公告称，公司第五届董事会第十三次会议审议通过了《公司 2025年半年度报告及其摘要》等多项议案。 （文章来源：证券日报） ...

我武生物（SZ 300357，收盘价：27.07元）8月21日晚间发布半年度业绩报告称，2025年上半年营业收 入约4.84亿元，同比增加12.81%；归属于上市公司股东的净利润约1.77亿元，同比增加18.61%；基本每 股收益0.3381元，同比增加18.63%。 （文章来源：每日经济新闻） ...

Core Viewpoint - Iwubio announced a revenue of 484 million yuan for the first half of 2025, representing a year-on-year growth of 12.81% [1] - The net profit attributable to shareholders reached 177 million yuan, with a year-on-year increase of 18.61% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 173 million yuan, showing a year-on-year growth of 21.97% [1] Financial Performance - Revenue for the first half of 2025: 484 million yuan, up 12.81% year-on-year [1] - Net profit attributable to shareholders: 177 million yuan, up 18.61% year-on-year [1] - Net profit after deducting non-recurring gains and losses: 173 million yuan, up 21.97% year-on-year [1]

Core Insights - The company focuses on its main business and enhances its allergen product pipeline, particularly in the field of allergic disease diagnosis and treatment [1] Financial Performance - The company achieved operating revenue of 484 million yuan, an increase of 12.81% compared to the same period last year [1] - The net profit attributable to shareholders was 177 million yuan, reflecting an 18.61% increase year-on-year [1] Product Sales Performance - Sales revenue from dust mite drops reached approximately 454.66 million yuan, up by 10.51% year-on-year [1] - Sales revenue from Artemisia pollen sublingual drops was about 21.02 million yuan, showing a significant increase of 71.37% compared to the previous year [1] - Sales revenue from skin prick solution amounted to approximately 6.33 million yuan, marking a substantial growth of 104.38% year-on-year [1] - The rapid growth in sales of Artemisia pollen sublingual drops and skin prick solution is primarily attributed to the company's increased marketing efforts for these products [1]

Meeting Announcement - Zhejiang WoBio Technology Co., Ltd. will hold its first extraordinary general meeting of shareholders for 2025 on September 12, 2025, at 14:30 [1] - The meeting will utilize a combination of on-site voting and online voting [1] Meeting Details - The meeting is convened in accordance with the resolutions of the company's fifth board of directors' thirteenth meeting [1] - On-site meeting time: September 12, 2025, at 14:30 [1] - Online voting will be available on September 12, 2025, from 9:15 to 15:00 through the Shenzhen Stock Exchange trading system [1][2] Eligibility to Attend - All shareholders registered with voting rights as of September 8, 2025, are entitled to attend the meeting [2] - Shareholders can appoint proxies to attend and vote on their behalf, and the proxy does not need to be a shareholder of the company [2] Agenda Items - The meeting will review the proposal to reappoint Rongcheng Accounting Firm as the company's auditing institution for the year 2025 [3] - The proposal regarding the reappointment is significant for minority investors and will require separate voting results disclosure [3] Registration Process - Corporate shareholders must register through their legal representatives or authorized agents, providing necessary documentation [5] - Individual shareholders must present their identification for registration, and proxies must provide authorization documents [5] Voting Procedures - Shareholders can vote in person at the meeting or through the online voting system provided by the Shenzhen Stock Exchange [4][9] - Specific voting procedures and requirements for online participation are detailed in the provided attachments [9]